Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.

Frontiers in immunology - 1 Jan 2021

Li Xiaohua, Wang Yuntao, Li Xuebing, Feng Gang, Hu Sheng, Bai Yifeng

Abstract excerpt

The treatment of non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs) has been proven to induce lasting tumor remission. Screening suitable populations for immunotherapy through predictive markers is an important approach to improving the clinical benefits of patients. Evidence has shown that there may be a close connection between NOTCH signaling and the tumor microenvironment (TME)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Inflammation

Share to Receptors, Notch

Share to Survival Analysis

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 34305884
DOI: 10.3389/fimmu.2021.638763
PMCID: PMC8302260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.PMID 34305884Read ↗

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

[Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].Semantic proximity Read ↗

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutationsSemantic proximity Read ↗

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Semantic proximity Read ↗

Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC.Semantic proximity Read ↗

Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma.Semantic proximity Read ↗

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read ↗

Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.